Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma

February 13, 2018

Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab vs ipilimumab alone in patients with advanced, unresectable melanoma

Published on 02/12/2018

previous post: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): An open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group
next post: Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome